{"nctId":"NCT02099006","briefTitle":"Novel Topical Therapies for the Treatment of Genital Pain","startDateStruct":{"date":"2013-11"},"conditions":["Female Genital Diseases"],"count":9,"armGroups":[{"label":"Medications","type":"EXPERIMENTAL","interventionNames":["Drug: Amitriptyline","Drug: Baclofen","Drug: Ketoprofen","Drug: Ketamine","Drug: Loperamide","Drug: Gabapentin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"Amitriptyline","otherNames":["Elavil"]},{"name":"Baclofen","otherNames":["Lioresal"]},{"name":"Ketoprofen","otherNames":["Orudis","Oruvail","Nexcede","Orudis KT"]},{"name":"Ketamine","otherNames":["Ketalar"]},{"name":"Loperamide","otherNames":["Imodium","Imotil","Kaopectate"]},{"name":"Gabapentin","otherNames":["Neurontin"]},{"name":"placebo","otherNames":["Cetaphil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Women between ages of 18 and 65 who complain of localized provoked vulvar pain and meet the criteria for the diagnosis of localized provoked vulvodynia. Patients who have failed or have been unable to tolerate previous attempts at systematic therapy or surgery will be specifically recruited.\n\nExclusion Criteria:\n\n1. The presence of a dermatologic or neurologic condition which is determined by the investigator to be the primary cause of the patient's pain.\n2. Allergy to any of the medications or the base itself.\n3. Concurrent use of the following medications. . The patient may enroll in the study after a two week washout from these medications. Patients may need to receive approval from the prescribing physician before stopping these medications. Failure to obtain approval for medication cessation would be cause for exclusion.\n\nGabapentin (NeurontinTM) Amitriptyline (ElavilTM) Nortriptyline (PamelorTM) Desipramine (NorpraminTM) Tramadol (UltramTM, ConZipTM, RybixTM, RysoltTM, Ultram ERTM) Pregabalin (LyricaTM) Baclofen","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Daily Genital Pain.","description":"Each subject was asked to keep a symptom diary recording her daily genital pain, measured on a 10 point Likert scale. A score of \"0\" was defined as no pain and a score of \"10\" was defined as worst imaginable pain. These daily values were collected and a mean pain score for the period of treatment was calculated.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.94"},{"groupId":"OG001","value":"2.92","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"2.45"},{"groupId":"OG001","value":"2.77","spread":"2.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.70","spread":"2.92"},{"groupId":"OG001","value":"3.41","spread":"2.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.87","spread":"2.74"},{"groupId":"OG001","value":"3.61","spread":"2.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.05","spread":"3.34"},{"groupId":"OG001","value":"5.05","spread":"3.45"}]}]}]},{"type":"SECONDARY","title":"Reduction in Tampon Test Pain","description":"Reduction in the pain, as measured on a 10 point Likert scale, associated with the insertion and removal of a tampon. This is a validated surrogate for pain associated with intercourse. Subjects were asked to insert and remove a tampon each week and report the degree of pain associated with this. A score of \"0\" was defined as no pain, and a score of \"10\" was defined as worst imaginable pain.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"2.75"},{"groupId":"OG001","value":"5.29","spread":"3.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.92","spread":"3.56"},{"groupId":"OG001","value":"5.92","spread":"3.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.125","spread":"3.57"},{"groupId":"OG001","value":"4.875","spread":"3.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.17","spread":"3.18"},{"groupId":"OG001","value":"6.0","spread":"3.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.43","spread":"2.75"},{"groupId":"OG001","value":"5.36","spread":"3.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":[]}}}